{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T02:18:34Z","timestamp":1768789114999,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1053\/j.seminoncol.2019.10.005","type":"journal-article","created":{"date-parts":[[2019,11,10]],"date-time":"2019-11-10T23:44:00Z","timestamp":1573429440000},"page":"403-407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology\u2606"],"prefix":"10.1053","volume":"46","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Carver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-1943","authenticated-orcid":false,"given":"Sebastian","family":"Szmit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Salvatorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Minotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2019.10.005_bib0001","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population based cohort study","volume":"165","author":"Dahlen","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0002","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ajh.24174","article-title":"Clinical features of pulmonary arterial hypertension in patients receiving dasatinib","volume":"90","author":"Shah","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0003","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0004","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0005","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.24360","article-title":"Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"issue":"132","key":"10.1053\/j.seminoncol.2019.10.005_bib0006","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"26","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0007","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","article-title":"Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML","volume":"59","author":"Valent","year":"2017","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0008","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0009","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00277-016-2820-x","article-title":"Identification, prevention and management of cardiovascular risk in chronic myeloid leukemia patients candidate to ponatinib: an expert opinion","volume":"96","author":"Breccia","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0010","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0011","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1161\/CIRCULATIONAHA.115.018351","article-title":"Cardiovascular complications of novel multiple myeloma treatments","volume":"133","author":"Li","year":"2016","journal-title":"Circulation"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0012","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0013","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"8","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0014","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/bjh.14708","article-title":"A retrospective analysis of 3954 patients in phase 2\/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma","volume":"178","author":"Laubach","year":"2017","journal-title":"Brit J Haem"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0015","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.hfc.2016.12.001","article-title":"Proteasome inhibtors as a potential cause of heart failure","volume":"13","author":"Koulaouzidis","year":"2017","journal-title":"Heart Fail Clin"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0016","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2018.03.022","article-title":"Mechanism of cardiovascular toxicity by proteasome inhibitors: new paradigm derived from clinical and pre-clinical studies","volume":"828","author":"Gavazzoni","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11936-018-0618-y","article-title":"Cardiovascular complications of multiple myeloma treatment: evaluation, management and prevention","volume":"20","author":"Lee","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0018","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1182\/asheducation-2013.1.684","article-title":"Cancer-associated thrombosis","volume":"2013","author":"Connolly","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0019","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1160\/TH17-03-0193","article-title":"Apixaban and dalteparin in active malignancy associated venous thromboembolism","volume":"117","author":"McBane","year":"2017","journal-title":"The ADAM VTE Trial. Thromb Haemost"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0020","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"16","key":"10.1053\/j.seminoncol.2019.10.005_bib0021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12959-018-0176-2","article-title":"COSIMO-patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study","volume":"4","author":"Cohen","year":"2018","journal-title":"Thromb J"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0022","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0023","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1634\/theoncologist.2015-0253","article-title":"Ponatinib: accelerated disapproval","volume":"20","author":"Gainor","year":"2015","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0024","unstructured":"Center For Drug Evaluation And Research (2012) Application Number: 203469orig1s000. Clinical pharmacology and biopharmaceutics review(s) (Reference ID: 3197238)"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0026","unstructured":"Center For Drug Evaluation And Research (2012) Application Number: 205552Orig1s000. Clinical pharmacology and biopharmaceutics review(s) (Reference ID: 3349368)"},{"key":"10.1053\/j.seminoncol.2019.10.005_bib0027","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/hon.2503","article-title":"Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding","volume":"36","author":"Boriani","year":"2018","journal-title":"Hematol Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775419300028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775419300028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:54:22Z","timestamp":1758804862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775419300028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0093775419300028"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2019.10.005","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology\u2606","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2019.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}